How Can We Help?
You are here:
< Back

Tribendimidine is a broad-spectrum anthelmintic agent developed in China, at the National Institute of Parasitic Diseases in Shanghai. It is a derivative of amidantel.[1]

In clinical trials, it was highly effective in treating ankylostomiasis, ascariasis and enterobiasis.[2] It is also effective against clonorchiasis.[3] However, animal studies suggest it is ineffective in treating Schistosoma mansoni or Fasciola hepatica disease.[1] The drug has also performed well in trials against opisthorchiasis, curing about 70% of cases.[4]

Tribendimidine is manufactured by Shandong Xinhua Pharmaceutical Company Limited in Zibo, Shandong, China. It was approved by the China Food and Drug Administration in 2007.[citation needed]

References

  1. ^ a b Keiser J, Shu-Hua X, Chollet J, Tanner M, Utzinger J (March 2007). "Evaluation of the in vivo activity of tribendimidine against Schistosoma mansoni, Fasciola hepatica, Clonorchis sinensis, and Opisthorchis viverrini". Antimicrobial Agents and Chemotherapy. 51 (3): 1096–1098. doi:10.1128/AAC.01366-06. PMC 1803157. PMID 17194822. Free full text.
  2. ^ Xiao SH, Hui-Ming W, Tanner M, Utzinger J, Chong W (April 2005). "Tribendimidine: a promising, safe and broad-spectrum anthelmintic agent from China". Acta Tropica. 94 (1): 1–14. doi:10.1016/j.actatropica.2005.01.013. PMID 15777691.
  3. ^ Zhang H, Liu C, Zheng Q (December 2019). "Development and application of anthelminthic drugs in China". Acta Tropica. 200: 105181. doi:10.1016/j.actatropica.2019.105181. PMID 31542370.
  4. ^ Kelland K (2010-11-24). "New drug shows promise against Asian liver fluke". Reuters.
Categories
Table of Contents